Thermo Fisher Scientific upgrades Quick to Clinic

By The Science Advisory Board staff writers

June 15, 2021 -- Thermo Fisher Scientific is showcasing a new version of its Quick to Clinic service for biologic drug developers at the BIO Digital 2021 conference, which is being held June 14-18.

The new version of Quick to Clinic utilizes Thermo Fisher's Gibco Freedom ExpiCHO royalty-free, high-yield expression system that can scale from a research and development environment, according to the firm. It is designed to enable biopharma companies to reach phase I trials and file for investigational new drug (IND) reviews with the U.S. Food and Drug Administration (FDA) in as little as 13 months from transfection.

Quick to Clinic also supports activities such as cell line development, process fit, analytical development, and qualification, Thermo Fisher said.

As a result, companies developing mammalian recombinant proteins can utilize the platform to ramp up quickly from the discovery phase, leveraging toxicology and good manufacturing practices material and documentation provided by Quick to Clinic to file for an IND in a more expedited manner, according to Thermo Fisher.

Thermo Fisher inks U.K. agreement to develop advanced workflows
Thermo Fisher Scientific has signed an agreement with the U.K.'s University of Sheffield to develop advanced workflows for characterizing and monitoring...
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.
Thermo Fisher to open cell center, debut microscope
Thermo Fisher Scientific has announced it will open a cell therapy center with the University of California, San Francisco. The company has also unveiled...
Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were...
Thermo Fisher to acquire PPD for $17.4B
Thermo Fisher Scientific announced it will acquire clinical research services company PPD for a total cash purchase price of $17.4 billion plus the...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter